|
Real-time Estimate
Cboe BZX
18:36:00 03/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 89.63 USD | -0.07% |
|
+0.35% | +35.00% |
| 08-24 | Dexcom Insider Sold Shares Worth $2,408,242, According to a Recent SEC Filing | MT |
| 08-13 | Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating | MT |
Company Valuation: DexCom, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 52,042 | 43,740 | 47,945 | 30,377 | 25,885 | 33,845 | - | - |
| Change | - | -15.95% | 9.61% | -36.64% | -14.79% | 30.75% | - | - |
| Enterprise Value (EV) 1 | 52,692 | 45,068 | 49,813 | 31,073 | 26,209 | 33,084 | 32,784 | 31,969 |
| Change | - | -14.47% | 10.53% | -37.62% | -15.65% | 26.23% | -0.91% | -2.49% |
| P/E | 346x | 138x | 95.5x | 54.8x | 31.8x | 36x | 30.2x | 24.9x |
| PBR | 23.1x | 20.5x | 23.1x | 15.1x | 9.3x | 11.9x | 9.92x | 7.64x |
| PEG | - | 1x | 1.6x | 5.94x | 0.7x | 1.9x | 1.6x | 1.2x |
| Capitalization / Revenue | 21.3x | 15x | 13.2x | 7.53x | 5.55x | 6.47x | 5.84x | 5.24x |
| EV / Revenue | 21.5x | 15.5x | 13.8x | 7.7x | 5.62x | 6.33x | 5.65x | 4.95x |
| EV / EBITDA | 111x | 60x | 49.1x | 28.1x | 19.4x | 19.9x | 17.1x | 14.4x |
| EV / EBIT | 142x | 92.9x | 69.3x | 41x | 27x | 26.5x | 22.7x | 18.6x |
| EV / FCF | 989x | 148x | 97.3x | 49.3x | 24.3x | 32.4x | 26.9x | 21.8x |
| FCF Yield | 0.1% | 0.68% | 1.03% | 2.03% | 4.11% | 3.09% | 3.72% | 4.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.3875 | 0.82 | 1.3 | 1.42 | 2.09 | 2.495 | 2.969 | 3.596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,448 | 2,910 | 3,622 | 4,033 | 4,662 | 5,230 | 5,800 | 6,461 |
| EBITDA 1 | 472.7 | 751.6 | 1,014 | 1,105 | 1,349 | 1,666 | 1,920 | 2,218 |
| EBIT 1 | 370.7 | 485.1 | 718.6 | 757.1 | 969.3 | 1,247 | 1,445 | 1,722 |
| Net income 1 | 154.7 | 341.2 | 541.5 | 576.2 | 836.3 | 974.4 | 1,149 | 1,409 |
| Net Debt 1 | 650.1 | 1,328 | 1,868 | 695.9 | 323.2 | -761.1 | -1,061 | -1,877 |
| Reference price 2 | 134.24 | 113.24 | 124.09 | 77.77 | 66.37 | 89.69 | 89.69 | 89.69 |
| Nbr of stocks (in thousands) | 387,688 | 386,258 | 386,374 | 390,595 | 390,016 | 377,361 | - | - |
| Announcement Date | 10/02/22 | 09/02/23 | 08/02/24 | 13/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.95x | 6.33x | 19.86x | -.--% | 33.85B | |
| 31.69x | 4.28x | 16.43x | 2.33% | 191B | |
| 19.8x | 3.57x | 12.75x | 3.17% | 118B | |
| 18.42x | 0.21x | 13.39x | 0.71% | 64.19B | |
| 29.93x | 7.38x | 19.05x | 1.33% | 51.49B | |
| 36.14x | 3.47x | 11.9x | 2.09% | 51.08B | |
| 46.86x | 1.34x | 12.44x | 0.2% | 31.85B | |
| 39.96x | 7x | 25.11x | 0.26% | 24.11B | |
| 18.71x | 2.93x | 10.5x | 1.5% | 22.96B | |
| 24.81x | 3.74x | 13.14x | 1.16% | 22.46B | |
| Average | 30.23x | 4.02x | 15.46x | 1.28% | 61.11B | |
| Weighted average by Cap. | 28.84x | 3.91x | 15.22x | 1.82% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXCM Stock
- Valuation DexCom, Inc.
Select your edition
All financial news and data tailored to specific country editions
